SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently driving intense debate as investors weigh strong government contract momentum against skepticism from figures like Michael Burry, whose recent commentary has fueled volatility. Sentiment is further polarized by a high-profile presidential endorsement, which has sparked aggressive discussion about potential market manipulation versus legitimate valuation corrections in the AI software sector.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying as investors digest a stronger-than-expected operational update, featuring a significant cash position and a clear ramp-up in production for optical engines targeting AI data centers. The community is actively discussing the companys strategic integration with major industry players like Marvell and the potential for a gamma squeeze as short interest meets limited share availability.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate whether the company is a deep-value opportunity or a struggling incumbent in the face of competitive pressure from agentic AI. While community members are polarized over recent price declines, the core discussion focuses on the firm's cash-rich, debt-free balance sheet and its potential for a turnaround through its ongoing strategic pivot toward enterprise AI orchestration.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense momentum as the community debates whether the stock's parabolic surge is supported by structural demand for its photonics technology or if it has entered bubble territory. Investors are closely tracking high-volume order announcements and hyperscaler deployment timelines, fueling a fierce battle between long-term bulls looking for rerating and skeptics warning of extreme valuation risks.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is facing a sharp sell-off driven by a UBS downgrade, which cited concerns that AI integrationspecifically the influence of Anthropics Claudecould erode traditional seat-based software margins and pricing power. While the stock has seen heavy institutional distribution, many in the community remain divided, with some viewing the technical breakdown as a generational buying opportunity based on long-term enterprise utility, while others fear the model shift threatens the core business trajectory.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare stock is currently surging following a robust fourth-quarter earnings report that featured a revenue beat and strong forward-looking guidance driven by massive demand for its AI infrastructure. Investors are actively debating the company's long-term potential as a critical backbone for agentic AI, with the community focused on whether this performance signals a broader recovery for the software sector.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is capturing market attention as investors speculate on potential integration with upcoming technological developments, while also benefiting from broader retail enthusiasm and discussions around memetic growth. The community remains highly polarized, with some anticipating significant price appreciation driven by mass adoption and speculative catalysts, while others emphasize the importance of long-term patience and caution against market volatility.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is capturing significant community attention as investors weigh its deep discount to cash-on-hand against the high-stakes potential of its lead candidate, azenosertib, with pivotal trial data expected soon. While some traders are bullish on institutional accumulation and the possibility of a buyout, others remain cautious, citing the company's high cash burn rate, recent strategic restructuring, and a history of volatility.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is experiencing significant momentum as investors increasingly view the company as a key proxy for SpaceX's anticipated multi-trillion dollar IPO. The community is actively debating the company's valuation upside tied to its satellite spectrum deals and SpaceX equity holdings, fueling a heated discussion on potential short squeezes versus long-term value accumulation.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon is currently seeing significant market activity as investors debate the potential of a $12 billion buyout offer from Sun Pharma, with high volume and volatile price action fueling intense community discussion. While some traders are loading up on positions expecting a formal deal, others are dismissing the reports as speculative, causing a divide between those chasing the M&A momentum and skeptics wary of the company's significant debt load.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LENSAR (NASDAQ:LNSR) Upgraded at Lake Street Capital

Lake Street Capital raised LENSAR from a "hold" rating to a "buy" rating and set a $10.00 price objective for the company in a research note on Wednesday...

LENSAR Q4 Earnings Call Highlights

LENSAR (NASDAQ:LNSR) executives used the company's fourth-quarter and full-year 2025 earnings call to outline how the cataract-laser maker plans to reaccelerate growth as a standalone company...

LENSAR (NASDAQ:LNSR) Releases Earnings Results, Misses Expectations By $0.02 EPS

LENSAR (NASDAQ:LNSR - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.02). The firm had revenue of $16.03 million for the quarter, compared to analyst estimates of $20.30...

LENSAR Stock Plunges Alcon Scraps Merger After Prolonged Regulatory Review

Alcon cancels $356 million LENSAR merger due to regulatory delays and FTC opposition, adding pressure on shares.read more...

<ul class="summary-bullets"><li>Lensar said in a statement that it is disappointed with the outcome and the Federal Trade Commission's intent to challenge the deal.</li><li>Alcon agreed to acquire LENSAR in March 2025 for a total potential consideration of up to $16.75 per share.</li><li>Lensar, despite the termination, will retain the $10.0 million deposit contemplated by the merger agreement, it said.</li></ul>&nbsp;Shares of LENSAR, Inc. (NSR) slumped 24% after hours on Monday after the company terminated its merger agreement with eye care company Alcon Research, LLC (ALC).The commercial-stage medical device company Lensar said on Monday that the company decided to terminate the deal after the two companies concluded that it is in the best interest of both. Lensar further added that the deal is unlikely to receive necessary regulatory approvals in the U.S. by April 23 or even by an extended deadline of July 23.Lensar said in a statement that it is disappointed with the outcome and the Federal Trade Commission's intent to challenge the deal.<h2 class="st-heading-2">The Deal That Fell Through</h2>Alcon agreed to acquire LENSAR in March 2025 for a total potential consideration of up to $16.75 per share. This included an upfront payment of $14 per share in cash and an additional non-tradeable contingent value right offering up to $2.75 per share in cash. Alcon then said that the transaction is anticipated to close in mid-to-late 2025.However, last month Lensar said that it now expects the transaction to close only by the first half of 2026 as the two companies continue to cater to the FTC’s demand for additional information pertaining to the acquisition.“...the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission’s opposition,” said Alcon CEO David J. Endicott. Lensar, however, will retain the $10.0 million deposit contemplated by the merger agreement, it said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LNSR stock stayed within the ‘bullish’ territory while sentiment around ALC remained ‘neutral’.<a href="https://stocktwits.com/symbol/LNSR">LNSR stock</a> has dropped 34% over the past 12 months while <a href="https://stocktwits.com/symbol/ALC">ALC shares</a> fell 13%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-shares-rise-as-company-begins-enrollment-in-gene-therapy-safety-enhancement-study/cZ3PezERIQd">Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback

Lensar said that its deal with Alcon is unlikely to receive necessary regulatory approvals in the U.S. by April 23 or even by July 23. 

Equity

Lensar said that its deal with Alcon is unlikely to receive necessary regulatory approvals in the U.S. by April 23 or even by July 23. 


Alcon Ends Merger Agreement With LENSAR After FTC Opposition

(RTTNews) - Alcon Inc. (ALC) announced on Monday that it has agreed with LENSAR, Inc. (LNSR) to terminate their previously announced merger agreement...

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ: LNSR) to terminate...

LENSAR (NASDAQ:LNSR) Stock Price Down 0.9% - Here's Why

LENSAR (NASDAQ:LNSR) Stock Price Down 0.9% - Should You Sell...

LENSAR (LNSR) Projected to Post Earnings on Thursday

LENSAR (NASDAQ:LNSR) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

LENSAR (NASDAQ:LNSR) Stock Price Up 0.6% - Here's Why

LENSAR (NASDAQ:LNSR) Trading Up 0.6% - Time to Buy...

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

LNSR
LENSAR Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LNSR News

LNSRLENSAR Inc